NEULANDLAB Stock View

Neuland Laboratories Ltd
stock-view-header

₹ 5,312.75

icon -192.80 | -3.62
Market Cap ₹( Cr.)
68,161.99
Proj. P/E (x)
24.92
Proj. P/BV (x)
Proj. ROE (%)
24.40
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)
15,930.00

Stock View

STRONG BUY

Last Updated On.
03-Dec-2023
 

The average score for Neuland Laboratories Ltd stands at 8 against 9, three months back.

Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The Company provide solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
4,375.01
100 DMA(₹)
3,991.09
200 DMA(₹)
3,122.72
52 Weeks Range
1,323.10     5,605.35

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required